Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation
暂无分享,去创建一个
A. Hartkopf | S. Biskup | A. Rabsteyn | F. Battke | D. Hadaschik | H. Zelba | S. Kayser | P. Latzer | C. Kyzirakos | Alex McQueeney | Oliver Bartsch | Johannes Harter
[1] Elizabeth A. Peters,et al. Editorial Board , 2014, Neuroscience Letters.
[2] Yu Qin,et al. Neoantigen: A New Breakthrough in Tumor Immunotherapy , 2021, Frontiers in Immunology.
[3] S. Tolaney,et al. Tumor mutational burden as a predictor of immunotherapy response in breast cancer , 2021, Oncotarget.
[4] A. Stenzl,et al. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report , 2021, Journal for ImmunoTherapy of Cancer.
[5] H. Redmond,et al. The LOCalizer Radiofrequency Identification System: An Effective New Technology for Localizing Non-Palpable Breast Lesions for Surgery , 2020, Surgical innovation.
[6] A. Iwasaki,et al. Why and How Vaccines Work , 2020, Cell.
[7] Ying S. Ting,et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer , 2020, Cell.
[8] S. Biskup,et al. A Highly Specific Assay for the Detection of SARS-CoV-2–Reactive CD4+ and CD8+ T Cells in COVID-19 Patients , 2020, The Journal of Immunology.
[9] J. Lai,et al. Peptide-Based Vaccines: Current Progress and Future Challenges , 2019, Chemical reviews.
[10] E. Mittendorf,et al. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial , 2019, Clinical Cancer Research.
[11] R. Hollingsworth,et al. Turning the corner on therapeutic cancer vaccines , 2019, npj Vaccines.
[12] L. Wilson,et al. Is Proton Therapy a “Pro” for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database , 2019, Front. Oncol..
[13] K. To,et al. Recent Advances in the Treatment of Breast Cancer , 2018, Front. Oncol..
[14] H. Rammensee,et al. Personalized cancer vaccines: adjuvants are important, too , 2018, Cancer Immunology, Immunotherapy.
[15] Li Ding,et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.
[16] M. Schubach,et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report , 2018, Journal of Translational Medicine.
[17] J. Utikal,et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.
[18] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[19] S. Siesling,et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer , 2017, Breast Cancer Research and Treatment.
[20] G. Viale,et al. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper® , 2017, Breast Cancer Research.
[21] I. Mellman,et al. Neo approaches to cancer vaccines , 2015, Science.
[22] E. Mardis,et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.
[23] Benjamin Schubert,et al. OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..
[24] D. McNeel,et al. Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[25] A. Chicheł,et al. Brachytherapy in breast cancer: an effective alternative , 2014, Przeglad menopauzalny = Menopause review.
[26] Hiroaki Tanaka,et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.
[27] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.
[28] C. Slingluff. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? , 2011, Cancer journal.
[29] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[30] Melissa Bondy,et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.
[31] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] N. Shastri,et al. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. , 2002, Annual review of immunology.
[33] I. Barillot,et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.
[34] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[35] D. Dunlop. RECENT ADVANCES IN TREATMENT , 1955 .